Documentation

Reports And Documents

Documentation

Financial Calendar 2018

Here we report the financials of 2018

Q1 Report, 2018

31 January, 2018

Q2 Report, 2018

30 April, 2018

Q3 Report, 2018

31 July, 2018

Bokslutskommité, 2018

31 October, 2018

Documentation

Financial Calendar 2017

Here we report the financials of 2017

Interim Report, 2017

31 July, 2017

Year End Report, 2017

31 October, 2017

Annual Report, 2018

14 November, 2017

Annual General Meeting, 2017

Conducted December 5, 2017

Sharing Information

Dividends And Transparency

Dividends

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development. There is a risk that future cash flows will not exceed the company’s capital requirements and that future AGMs will not decide on future dividends.

Transparency

Shares in NextCell Pharma AB are traded on Aktietorget as per July 2017.

List of 5 largest shareholders as per 2018-03-31

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Owners / Shares / Percentage

Diamyd Medical AB* / 1 173 723 / 13.8 Avanza Pension / 972 170 / 11,43 Anders Essen-Möller** / 546 898 / 6,43 Bertil Lindkvist / 444 833 / 5,23 Göran Ofsen / 380 192 / 4,47 Other Owners / 4 987 581*** / 58,64***
     
* NextCell’s Board Chairman Anders Essen-Möller owns 16.8% of the shares and 40.1% of the votes in Diamyd Medical AB. ** Anders Essen-Möller is the Board Chairman of NextCell. *** Numbers are close approximations and can deviate slightly form reality

Share price

The current share price is available on Aktietorget. https://ir.aktietorget.se/company/overview/?id=456&InstrumentID=SE0009723125

Documentation

Corporate Gorvenance

Auditor

Bo Åsell Öhrlings PricewaterhouseCoopers AB (PwC) Torsgatan 21, 113 97 Stockholm Bo Åsell is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden

Articles Of Association

Nomination Committee

No information available

Incentive Programmes

NextCell Pharma AB currently has no active incentive programmes.

Documentation

IPO

Instructions For Subscription Registration

Instructions are included in the subscription form.

Documentation

Aktietorget

NextCell Pharma AB is listed on the AktieTorget stock exchange since July 2017.

Link to aktietorget

Link to NextCell’s IR page on Aktietorget

   
Contact Karolinska Institutet Science Park Hälsovägen 7, 141 57 Huddinge info@nextcellpharma.com +46 (0)8 735 55 95